Blackrock, INC Schedule 13G passive stakes
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant Stake in Diamond Hill Investment Group, Filing Shows 7.9% Ownership
BlackRock, Inc. has filed an Amendment No. 14 to Schedule 13G, disclosing a beneficial ownership of 7.9% of Diamond Hill Investment Group Inc.'s Class A Stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 6.1% of DoorDash, Inc.'s Class A Stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a continued beneficial ownership of 10.1% of Dropbox Inc.'s Class A Stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, revealing an 11.7% beneficial ownership stake in Entegris, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.1% Passive Stake in Entergy Corp
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.1% of Entergy Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Entravision Communications Corporation's Class A Stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 9.0% Stake in Exelon Corporation
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.0% beneficial ownership stake in Exelon Corporation's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 7 to Schedule 13G, reporting a 6.9% beneficial ownership stake in Fate Therapeutics Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Passive Stake in Flowserve Corporation to 8.6%
BlackRock, Inc. has filed an Amendment No. 13 to its Schedule 13G, reporting a passive beneficial ownership of 8.6% of Flowserve Corporation's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.9% beneficial ownership stake in Forum Energy Technologies Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its continued passive beneficial ownership of 9.3% of HP Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.4% passive beneficial ownership stake in Herc Holdings Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% passive beneficial ownership stake in Investar Holding Corp. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, reporting a 9.6% beneficial ownership stake in Iridium Communications Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.2% of Axon Enterprise Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, reporting a 7.1% beneficial ownership stake in Bandwidth Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 9.9% beneficial ownership stake in BlueLinx Holdings Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Boosts Stake in Blueprint Medicines Corp to 8.0%
BlackRock, Inc. has disclosed an increased passive ownership stake of 8.0% in Blueprint Medicines Corp, holding over 5 million shares as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.7% beneficial ownership stake in Business First Bancshares, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G: BlackRock Discloses 5.8% Stake in Cardiff Oncology, Inc.
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Cardiff Oncology, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 8.2% of Castle Biosciences Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 12.8% of Clearwater Paper Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.9% passive beneficial ownership stake in CommScope Holding Company, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.8% Passive Stake in ConnectOne Bancorp
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% passive beneficial ownership stake in ConnectOne Bancorp Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.2% Passive Stake in Flex LTD Common Stock
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.2% of Flex LTD's common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant Passive Stake in Amicus Therapeutics, Disclosing 7.4% Ownership
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reaffirming its passive beneficial ownership of 7.4% of Amicus Therapeutics Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant 7.8% Stake in Arcturus Therapeutics, Files Updated Ownership Disclosure
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, confirming its beneficial ownership of 7.8% of Arcturus Therapeutics Holdings Inc. common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, disclosing a 4.9% beneficial ownership stake in Ares Management Corporation as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Stake in Arrowhead Pharmaceuticals, Disclosing 13.8% Beneficial Ownership
BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 13.8% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in Artiva Biotherapeutics, Inc. as of March 31, 2025, held in the ordinary course of business.